StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report released on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Stock Down 5.8 %
Shares of MNOV opened at $1.63 on Tuesday. The firm has a market capitalization of $79.95 million, a PE ratio of -10.19 and a beta of 0.75. The firm has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.49. MediciNova has a 52-week low of $1.12 and a 52-week high of $2.16.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities analysts expect that MediciNova will post -0.23 EPS for the current year.
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Recommended Stories
- Five stocks we like better than MediciNova
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Texas Roadhouse Stock Steering for New Highs This Year
- What Does a Stock Split Mean?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Retail Stocks Investing, Explained
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.